Jazz Pharmaceuticals (JAZZ) Profit After Tax (2010 - 2026)

Jazz Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at $293.1 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 416.86% year-over-year to $293.1 million in Q1 2026; TTM through Mar 2026 was $29.5 million, a 93.88% decrease from a year earlier, with the FY2025 full-year figure at -$356.1 million, down 163.58% from the prior year.
• Profit After Tax rose to $293.1 million in Q1 2026 per JAZZ's latest filing, from $203.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $293.1 million in Q1 2026 and bottomed at -$718.5 million in Q2 2025.
• The 5-year median for Profit After Tax is $113.4 million (2023), against an average of $11.6 million.
• Across the five-year window, Profit After Tax plunged 580.95% in 2022 and soared 8720.83% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$240.7 million in 2022, then soared by 139.11% to $94.2 million in 2023, then soared by 102.98% to $191.1 million in 2024, then grew by 6.45% to $203.5 million in 2025, then soared by 44.06% to $293.1 million in 2026.
• Per Business Quant, the three latest JAZZ Profit After Tax figures stand at $293.1 million (Q1 2026), $203.5 million (Q4 2025), and $251.4 million (Q3 2025).